{"id":8410,"date":"2021-12-16T13:28:03","date_gmt":"2021-12-16T18:28:03","guid":{"rendered":"https:\/\/puyapeptide.net\/product\/lisiraglide-cas-320367-13-3-er-en-glukagon-lignende-peptid-1-glp-1-receptoragonist\/"},"modified":"2021-12-16T13:28:03","modified_gmt":"2021-12-16T18:28:03","slug":"lisiraglide-cas-320367-13-3-er-en-glukagon-lignende-peptid-1-glp-1-receptoragonist","status":"publish","type":"product","link":"https:\/\/puyapeptide.net\/da\/product\/lisiraglide-cas-320367-13-3-er-en-glukagon-lignende-peptid-1-glp-1-receptoragonist\/","title":{"rendered":"Lisiraglide CAS 320367-13-3 er en glukagon-lignende peptid-1 (GLP-1) receptoragonist"},"content":{"rendered":"

Lisiraglide CAS 320367-13-3 er en glukagon-lignende peptid-1 (GLP-1) receptoragonist<\/strong><\/h2>\n

Produktnavn: Lixisenatide
\nSynonymer: Lixisenatide, >98%;lixisenatide;Lixisenatide|Lixisenatideacetat;Lixisenatidacetat;Lixisenatide USP\/EP\/BP
\nCAS: 320367-13-31
\n1O67S2161612616165
\nMW: 4858.53
\nEINECS:
\nProduktkategorier:
\nMol Fil: 320367-13-3.mol<\/p>\n

Lisiraglid er et glukagonlignende peptid-1 (GLP-1) receptoragonist, et hormon, der hj\u00e6lper med at normalisere blodsukkerniveauet. L\u00e6gemidlets sikkerhed og virkning blev evalueret i 10 kliniske fors\u00f8g, der inkluderede i alt 5.400 patienter med type 2-diabetes. I disse fors\u00f8g blev lisiramid evalueret b\u00e5de som monoterapi og i kombination med andre FDA-godkendte diabetesmedicin, herunder metformin, sulfonylurinstoffer, pioglitazon og basal insulin. I disse fors\u00f8g forbedrede brugen af lisiramid niveauerne af glykeret h\u00e6moglobin (en indikator for blodsukkerniveauer). Derudover blev mere end 6.000 patienter med type 2-diabetes i risiko for aterosklerotisk kardiovaskul\u00e6r sygdom behandlet med lisiramid eller placebo i Cardiovascular Outcomes Trial. Brugen af lisiramid hos disse patienter \u00f8gede ikke risikoen for u\u00f8nskede kardiovaskul\u00e6re h\u00e6ndelser. Lisiragide b\u00f8r ikke anvendes til behandling af patienter med type 1-diabetes eller patienter med forh\u00f8jede ketoner eller urin i blodet (diabetisk ketoacidose). De mest almindelige bivirkninger forbundet med lisiramid er kvalme, opkastning, hovedpine, diarr\u00e9 og svimmelhed. Hypoglyk\u00e6mi er en anden almindelig bivirkning hos patienter, der behandles med lisiramid og andre antidiabetiske l\u00e6gemidler, s\u00e5som sulfonylurinstoffer og\/eller basalafgr\u00f8der. Derudover er alvorlige overf\u00f8lsomhedsreaktioner (inklusive overf\u00f8lsomhed) blevet rapporteret i kliniske fors\u00f8g med Lisiragib.<\/p>\n

Lixisenatid er et l\u00e6gemiddel, der i \u00f8jeblikket anvendes til behandling af diabetes og er ogs\u00e5 en GLP-1-receptoragonist. Lixisenatid (Lyxumia) blev godkendt til markedsf\u00f8ring i Europa i 2013 og er en injicerbar diabetesbehandling baseret p\u00e5 Lixisenatid, som administreres \u00e9n gang dagligt sammen med anden medicin eller insulin til patienter, hvis blodsukkerniveauer kun kan kontrolleres med medicin.< &>
\n Bem\u00e6rkning af Lisiraglide CAS 320367-13-3<\/strong>
\nKun til forskningsbrug, ikke til human brug<\/p>\n","protected":false},"excerpt":{"rendered":"

Produktnavn: Lixisenatid
\nAcetat;Lixisenatid USP\/EP\/BP
\nCAS: 320367-13-3
\nMF: C215H347N61O65S
\nMW: 4858,53
\nMol Fil: 320367-3,13<\/p>\n","protected":false},"featured_media":2098,"comment_status":"open","ping_status":"closed","template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}}},"product_brand":[],"product_cat":[],"product_tag":[1280],"class_list":{"0":"post-8410","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_tag-lisiraglide-cas-320367-13-3-is-a-glucagon-like-peptide-1-glp-1-receptor-agonist-da","7":"desktop-align-left","8":"tablet-align-left","9":"mobile-align-left","11":"first","12":"instock","13":"shipping-taxable","14":"product-type-simple"},"_links":{"self":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product\/8410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/comments?post=8410"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/media\/2098"}],"wp:attachment":[{"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/media?parent=8410"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_brand?post=8410"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_cat?post=8410"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/puyapeptide.net\/da\/wp-json\/wp\/v2\/product_tag?post=8410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}